MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
20 févr. 2024 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter and full year financial results and its...
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
15 févr. 2024 06h05 HE
|
MannKind
MANNKIND ANNOUNCES ENROLLMENT GOAL COMPLETION OF INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING AFREZZA
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
02 janv. 2024 06h05 HE
|
MannKind
Sagard Healthcare purchased a 1% royalty in Tyvaso DPI® net salesPurchase price of $150 million; additional potential milestone payment of up to $50 million WESTLAKE VILLAGE, Calif., Jan. 02, 2024 ...
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
28 déc. 2023 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation Reports 2023 Third Quarter Financial Results
07 nov. 2023 16h00 HE
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs. 3Q 20223Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 20223Q 2023 Net income of $2M; Non-GAAP net...
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
06 nov. 2023 06h15 HE
|
MannKind
INHALE-3 clinical trial in patients living with type 1 diabetes fully enrolled. Will evaluate inhaled insulin (with basal insulin) vs. usual care.
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
31 oct. 2023 16h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial...
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
30 oct. 2023 06h15 HE
|
MannKind
Patent covers compositions of clofazimine, and methods for treating lung infectionsDevelopment of MNKD-101 (inhaled clofazimine) continues for the potential treatment of nontuberculous mycobacterial...
MannKind Corporation Announces Participation at Upcoming Conferences
05 sept. 2023 06h00 HE
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation Reports 2023 Second Quarter Financial Results
07 août 2023 16h00 HE
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 20232Q 2023 Endocrine Business Unit net revenues...